Evidence map›Paper›PMID 30379808›Full record

ArticlePloS one2018

Comparative evaluation of the Geenius HIV 1/2 Confirmatory Assay and the HIV-1 and HIV-2 Western blots in the Japanese population.

Makiko Kondo, Koji Sudo, Takako Sano, Takuya Kawahata, Ichiro Itoda, Shinya Iwamuro, Yukihiro Yoshimura, Natsuo Tachikawa, Yoko Kojima, Haruyo Mori and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Different approaches to HIV confirmation: a survey of three Italian regions.Frontiers in cellular and infection microbiology · 2026
    Article
  2. Article
  3. Article
  4. Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Makiko KondoDivision of Microbiology, Kanagawa Prefectural Institute of Public Health, Chigasaki, Kanagawa, Japan.
Koji SudoDepartment of Microbiology and Immunology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Takako SanoDivision of Microbiology, Kanagawa Prefectural Institute of Public Health, Chigasaki, Kanagawa, Japan.
Takuya KawahataVirology Section, Division of Microbiology, Osaka Institute of Public Health, Osaka, Osaka, Japan.ORCID 0000-0003-3336-4188
Ichiro ItodaShirakaba Clinic, Shinjuku-ku, Tokyo, Japan.
Shinya IwamuroAtsugi City Hospital, Atsugi, Kanagawa, Japan.
Yukihiro YoshimuraDepartment of Infectious Diseases, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Natsuo TachikawaDepartment of Infectious Diseases, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Yoko KojimaVirology Section, Division of Microbiology, Osaka Institute of Public Health, Osaka, Osaka, Japan.
Haruyo MoriVirology Section, Division of Microbiology, Osaka Institute of Public Health, Osaka, Osaka, Japan.
Hiroshi FujiwaraCenter for Infectious Diseases and Infection Control, Keio University Hospital, Shinjuku-ku, Tokyo, Japan.
Naoki HasegawaCenter for Infectious Diseases and Infection Control, Keio University Hospital, Shinjuku-ku, Tokyo, Japan.
Shingo KatoDepartment of Microbiology and Immunology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0002-8125-1981
Osaka Prefectural Institute of Public Health · JPKanagawa Prefectural Institute of Public Health · JPKeio University · JPKeio University Hospital · JPYokohama Municipal Citizen's Hospital · JPTsurugi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate diagnosis of earlier HIV infection is essential for treatment and prevention. Currently, confirmation tests of HIV infection in Japan are performed using Western blot (WB), but WB has several limitations including low sensitivity and cross-reactivity between HIV-1 and HIV-2 antibodies. To address these problems, a new HIV testing algorithm and a more reliable confirmation and HIV-1/2 differentiation assay are required. The Bio-Rad Geenius HIV-1/2 Confirmatory Assay (Geenius) has recently been approved and recommended for use in the revised guidelines for diagnosis of HIV infection by the Center for Disease Control and Prevention (USA). We made comprehensive comparison of the performance of Geenius and the Bio-Rad NEW LAV BLOT 1 and 2 (NLB 1 and 2) which are WB kits for HIV-1 and HIV-2, respectively, to examine if Geenius is a suitable alternative to these WB assays which are now being used in HIV testing in Japan. A total of 166 HIV-1 positive samples (146 from patients with established HIV-1 infection and 20 from patients with acute infection), five HIV-1 seroconversion panels containing 21 samples and 30 HIV-2 positive samples were used. In addition, a total of 140 HIV negative samples containing 10 false-positives on screening tests were examined. The sensitivity of Geenius and NLB 1 for HIV-1 positive samples was 99.3% and 98.6%, respectively. Geenius provided more positive results in the samples from acute infections and detected positivity 0 to 32 days earlier in seroconversion panels than NLB 1. NLB 2 gave positive results in 12.3% of HIV-1 positive samples. The sensitivity of both Geenius and NLB 2 for HIV-2 positive samples was 100%. The specificity of Geenius, NLB 1 and NLB 2 was 98.5%, 81.5% and 90.0%, respectively. Geenius is an attractive alternative to WB for confirmation and differentiation of HIV-1 and HIV-2 infections. The adaptation of Geenius to the HIV testing algorithm may be advantageous for rapid diagnosis and the reduction of testing costs.

Indexed as

HIV-1HIV-2AlgorithmsBlotting, WesternChromatography, AffinityFalse Positive ReactionsHIV AntibodiesHIV InfectionsHIV SeropositivityHumansJapanMass ScreeningReproducibility of ResultsSensitivity and SpecificityHIV Antibodies

Identifiers

PMID30379808
PMCPMC6209130
OpenAlexW2950844998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.